Quanterix Corporation

Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer

Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer

May 23, 2010

Quanterix Technology Shown To Be More Than 1,000 Times More Sensitive Than Standard Methods With Potential For Broad Application To Measure Biomarkers In Cancer, Autoimmune, and Neurological Diseases

T2 Biosystems, Inc.

T2 Biosystems Raises $15 Million in Series C Financing

T2 Biosystems Raises $15 Million in Series C Financing

May 25, 2010

Physic Ventures Leads Financing in Novel Technology to Enable Decentralized Diagnostics

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors

January 3, 2008

CAMBRIDGE, MA, January 3, 2008 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of Kenneth M. Bate, president and chief executive officer of NitroMed, Inc., to its Board of Directors.

T2 Biosystems, Inc.

T2 Biosystems Appoints John McDonough as CEO

T2 Biosystems Appoints John McDonough as CEO

January 3, 2008

Cambridge, MA -- January 3, 2008 – T2 Biosystems, Inc., a company developing the first portable medical diagnostic products which combine nanotechnology and miniaturized magnetic resonance imaging (MRI) technology, today announced the appointment of John McDonough as Chief Executive Officer. McDonough will also serve as a member of the Company’s board of directors.

Helicos BioSciences Corporation

Helicos BioSciences Enters into $20 Million Credit Facility with GE Healthcare Financial Services

Helicos BioSciences Enters into $20 Million Credit Facility with GE Healthcare Financial Services

January 4, 2008

CAMBRIDGE, Mass., Jan 04, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation announced today that it has closed a $20 million senior secured credit facility with GE Healthcare Financial Services. The Company will use the credit facility to support working capital and commercialization efforts.

Carbon Design Systems

Carbon Design Systems Raises $6 Million in Venture Funding After Successful 2007

Carbon Design Systems Raises $6 Million in Venture Funding After Successful 2007

January 9, 2008

Success Attributed to Carbon Model Studio Launch, New Customers, Partnerships with ARM, CoWare; Plans Move to New Corporate Headquarters to Support Hiring

WALTHAM, Mass.--(BUSINESS WIRE)--Carbon Design Systems™, the leading supplier of tools for the automatic creation, validation and deployment of virtual hardware models, today announced it has closed a round of funding totaling $6 million, after a successful Fiscal Year 2007.

Helicos BioSciences Corporation

Helicos BioSciences Announces MicroRNA Collaboration with miRNA Expert

Helicos BioSciences Announces MicroRNA Collaboration with miRNA Expert

January 9, 2008

Partnership with Dr. Victor Ambros to Expand Genomic Discoveries

CAMBRIDGE, Mass., Jan 09, 2008 (BUSINESS WIRE) -- Helicos BioSciences (Nasdaq:HLCS), a life science company focused on innovative genetic analysis technologies, announced today a formal collaboration with Dr. Victor Ambros to apply the quantitative power of True Single Molecule Sequencing (tSMS(TM)) to develop a single assay to characterize known species of microRNA (miRNA) as well as discover new non-coding RNAs.

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Closes Additional $9.75 Million in Financing

Pervasis Therapeutics Closes Additional $9.75 Million in Financing

January 15, 2008

Pioneer in regenerative cell-based therapies and devices announces additional funding in support of Vascugel® blood vessel repair therapeutic clinical trials and research into additional vascular and non-vascular disease applications

BG Medicine, Inc.

BG Medicine Announces Decision to Withdraw IPO

BG Medicine Announces Decision to Withdraw IPO

January 23, 2008

January 23, 2008 -- Waltham, Mass. BG Medicine, a medical diagnostics company, announced today that based on current market conditions, it has chosen not to proceed with its planned initial public offering at this time. The company has withdrawn its registration statement on Form S-1 as filed with the Securities and Exchange Commission.

Seventh Sense Biosystems, Inc.

Seventh Sense, Rox Anderson and Bob Langer Startup, Seeks to Collect Blood With No Pain

Seventh Sense, Rox Anderson and Bob Langer Startup, Seeks to Collect Blood With No Pain

May 20, 2010

Ryan McBride 5/20/10
Xconomy.com

Seventh Sense Biosystems wants to remove some of the hassle, expense, and pain of collecting blood for medical tests. The secretive startup has recently begun talks with major healthcare companies about its technology, which includes a device for collecting blood samples that almost anyone ought to be able to use without causing pain ... [read the full, original posting on Xconomy.com]